FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
Goldman Sachs analyst Ronald Keung raised the price target on Pinduoduo Inc. (NASDAQ: PDD) to $107.00 (from $95.00) while maintaining a Buy rating following earnings.
The analyst commented, "Factoring in strong 3Q results, we lift our revenue estimates by +8% to +12% and adj. operating profit... More
Elon Musk said in a series of tweets on Monday that Apple (NASDAQ: AAPL) threatened to withhold Twitter from its App Store without providing a reason why.
The Twitter owner and Tesla CEO tweeted: "Apple has also threatened to withhold Twitter from its App Store, but won't tell us... More
(Updated - November 28, 2022 3:22 PM EST)
The next Apple (NASDAQ: AAPL) iPhone series will be equipped with Sony Group's latest state-of-the-art image sensor, according to a report by Nikkei on Monday.
The sensor will be supplied to Apple... More
Retailer Williams-Sonoma (NYSE: WSM) was cut to Underweight from Equal-Weight by Morgan Stanley analyst Simeon Gutman on Monday, also lowering the firm's price target on the stock to $100 per share from $150.
Gutman told investors in a research note that earnings revisions could turn sharply negative in 2023 as the "impacts of reversion, recession & normalizing promotions appear... More
US Tiger Securities analyst Bo Pei raised the price target on Pinduoduo Inc. (NASDAQ: PDD) to $85.00 (from $80.00) while maintaining a Buy rating following earnings.
The analyst commented, "We are maintaining our BUY rating and raising our price target to $85 (was $80) after PDD beat 3Q revenue and profit estimates by a wide margin with... More
Deutsche Bank analyst David Begleiter weighed in on Univar Solutions Inc. (NYSE: UNVR) after the company confirmed that it has received a preliminary indication of interest from Brenntag SE regarding a potential takeover.
Begleiter believes Univar could be seeking an acquisition price of... More
Biogen (NASDAQ: BIIB) shares dipped Monday after a report by Science.org stated that a woman participating in a trial of experimental Alzheimer's treatment lecanemab had recently died from a brain hemorrhage.
According to the report, some researchers linked the brain hemorrhage to the drug. It is said to be the second death thought to be associated with lecanemab,... More
Truist Securities analyst Robyn Karnauskas weighed in on Biogen (NASDAQ: BIIB) following recent news of the second death reported for Alzheimer's drug lecanemab. The analyst highlights:
The recent news and AEs of the drug raise lots of questions whether... More
